Evaluation of OVOL1 and Filaggrin immunohistochemical expression and clinical relevance in psoriasis.
Filaggrin
Immunohistochemistry
OVOL1
Psoriasis
Journal
Diagnostic pathology
ISSN: 1746-1596
Titre abrégé: Diagn Pathol
Pays: England
ID NLM: 101251558
Informations de publication
Date de publication:
21 Jun 2024
21 Jun 2024
Historique:
received:
08
12
2023
accepted:
26
04
2024
medline:
22
6
2024
pubmed:
22
6
2024
entrez:
21
6
2024
Statut:
epublish
Résumé
Psoriasis is a disease of overactive immune system. OVOL1 and Filaggrin have been associated with many inflammatory skin lesions. To the best of our knowledge, the correlation between OVOL1 and Filaggrin in psoriasis was not previously investigated. This work aims to search the immunohistochemical expression and correlation between OVOL1 and Filaggrin in psoriasis. Slides cut from paraffin blocks of 30 psoriasis cases and 30 control subjects were stained with OVOL1 and Filaggrin. Clinicopathological data were correlated with the results of staining. OVOL1 and Filaggrin expression in epidermis showed a significant gradual reduction from normal skin to peri-lesional and psoriasis biopsies (P < 0.001). In contrast, psoriasis dermis showed a significant overexpression of OVOL1 in inflammatory cells in relation to peri-lesional biopsies (P < 0.002). OVOL1 demonstrated a significant direct correlation with Filaggrin expression in psoriasis (r = 0.568, P < 0.004). OVOL1 and Filaggrin expression in psoriasis skin epidermis demonstrated a statistically significant negative correlation with PASI score. OVOL1 and Filaggrin might be involved in psoriasis-associated inflammation and skin hyperproliferation. OVOL1 might have a protective barrier function in the skin and could be used to stratify progressive disease. Filaggrin may play a role in progression of psoriasis. OVOL1 inhibition could be considered in suppression of Filaggrin function. OVOL1 agonists may be beneficial in psoriasis treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Psoriasis is a disease of overactive immune system. OVOL1 and Filaggrin have been associated with many inflammatory skin lesions. To the best of our knowledge, the correlation between OVOL1 and Filaggrin in psoriasis was not previously investigated. This work aims to search the immunohistochemical expression and correlation between OVOL1 and Filaggrin in psoriasis.
MATERIALS AND METHODS
METHODS
Slides cut from paraffin blocks of 30 psoriasis cases and 30 control subjects were stained with OVOL1 and Filaggrin. Clinicopathological data were correlated with the results of staining.
RESULTS
RESULTS
OVOL1 and Filaggrin expression in epidermis showed a significant gradual reduction from normal skin to peri-lesional and psoriasis biopsies (P < 0.001). In contrast, psoriasis dermis showed a significant overexpression of OVOL1 in inflammatory cells in relation to peri-lesional biopsies (P < 0.002). OVOL1 demonstrated a significant direct correlation with Filaggrin expression in psoriasis (r = 0.568, P < 0.004). OVOL1 and Filaggrin expression in psoriasis skin epidermis demonstrated a statistically significant negative correlation with PASI score.
CONCLUSION
CONCLUSIONS
OVOL1 and Filaggrin might be involved in psoriasis-associated inflammation and skin hyperproliferation. OVOL1 might have a protective barrier function in the skin and could be used to stratify progressive disease. Filaggrin may play a role in progression of psoriasis. OVOL1 inhibition could be considered in suppression of Filaggrin function. OVOL1 agonists may be beneficial in psoriasis treatment.
Identifiants
pubmed: 38907248
doi: 10.1186/s13000-024-01491-4
pii: 10.1186/s13000-024-01491-4
doi:
Substances chimiques
Filaggrin Proteins
0
FLG protein, human
0
Intermediate Filament Proteins
0
OVOL1 protein, human
0
Biomarkers
0
DNA-Binding Proteins
0
Transcription Factors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
84Informations de copyright
© 2024. The Author(s).
Références
Arnold KA, Treister AD, Lio PA, Alenghat FJ. Association of Atherosclerosis Prevalence with Age, Race, and traditional risk factors in patients with psoriasis. JAMA Dermatol. 2019;155:5:622–3.
doi: 10.1001/jamadermatol.2018.5462
pubmed: 30785601
pmcid: 6506874
Bu J, Ding R, Zhou L, Chen X, Shen E. Epidemiology of Psoriasis and Comorbid diseases: a narrative review. Front Immunol. 2022;13:880201.
doi: 10.3389/fimmu.2022.880201
pubmed: 35757712
pmcid: 9226890
Papp KA, Gniadecki R, Beecker J, Dutz J, Gooderham MJ, Hong CH, Kirchhof MG, Lynde CW, Maari C, Poulin Y, Vender RB. Psoriasis Prevalence and Severity by Expert Elicitation. Dermatol Ther (Heidelb). 2021;11(3):1053–64.
doi: 10.1007/s13555-021-00518-8
pubmed: 33886086
Zhou X, Chen Y, Cui L, Shi Y, Guo C. Advances in the pathogenesis of psoriasis: from keratinocyte perspective. Cell Death Dis. 2022;13(1):81.
doi: 10.1038/s41419-022-04523-3
pubmed: 35075118
pmcid: 8786887
Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Mazaud C, Droitcourt C, Hughes C, Ingram JR, Naldi L, Chosidow O, Le Cleach L. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2017;12(12):CD011535.
pubmed: 29271481
Dai X, Schonbaum C, Degenstein L, Bai W, Mahowald A, Fuchs E. The ovo gene required for cuticle formation and oogenesis in flies is involved in hair formation and spermatogenesis in mice. Genes Dev. 1998;12:3452–63.
doi: 10.1101/gad.12.21.3452
pubmed: 9808631
pmcid: 317232
Nair M, Teng A, Bilanchone V, Agrawal A, Li B, Dai X. Ovol1 regulates the growth arrest of embryonic epidermal progenitor cells and represses c-myc transcription. J Cell Biol. 2006;173(2):253–64.
doi: 10.1083/jcb.200508196
pubmed: 16636146
pmcid: 2063816
Sun P, Vu R, Dragan M, Haensel D, Gutierrez G, Nguyen Q, et al. OVOL1 regulates Psoriasis-Like skin inflammation and Epidermal Hyperplasia. J Invest Dermatol. 2021;141(6):1542–52.
doi: 10.1016/j.jid.2020.10.025
pubmed: 33333123
Dragan M, Sun P, Chen Z, Ma X, Vu R, Shi Y, et al. Epidermis-intrinsic transcription factor Ovol1 Coordinately regulates barrier maintenance and Neutrophil Accumulation in Psoriasis-Like inflammation. J Invest Dermatol. 2022;142(3 Pt A):583–e5935.
doi: 10.1016/j.jid.2021.08.397
pubmed: 34461129
Zhang Y, Tu C, Wang S, Xiao S. Expression of skin barrier protein filaggrin in skin diseases without atopic dermatitis. J Biosci Med. 2018;6:101–12.
Zhao Y, Terron-Kwiatkowski A, Liao H, Lee SP, Allen MH, Hull PR, et al. Filaggrin null alleles are not associated with psoriasis. J Invest Dermatol. 2007;127(8):1878–82.
doi: 10.1038/sj.jid.5700817
pubmed: 17410197
Hemida AS, Mareae AH, Elbasiony ASA, Shehata WA. Plexin-B2 in psoriasis; a clinical and immunohistochemical study. J Immunoass Immunochem. 2020;41(4):718–28.
doi: 10.1080/15321819.2020.1741385
Zlobec I, Steele R, Terracciano L, Jass JR, Lugli A. Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol. 2007;60(10):1112–6.
doi: 10.1136/jcp.2006.044537
pubmed: 17182662
Ito T, Tsuji G, Ohno F, Uchi H, Nakahara T, Hashimoto-Hachiya A, et al. Activation of the OVOL1-OVOL2 Axis in the Hair Bulb and in Pilomatricoma. Am J Pathol. 2016;186(4):1036–43.
doi: 10.1016/j.ajpath.2015.12.013
pubmed: 26873447
Mócsai G, Gáspár K, Nagy G, Irinyi B, Kapitány A, Bíró T, et al. Severe skin inflammation and filaggrin mutation similarly alter the skin barrier in patients with atopic dermatitis. Br J Dermatol. 2014;170(3):617–24.
doi: 10.1111/bjd.12743
pubmed: 24251354
Liu J, Xu B, Zheng C, Gong Y, Garibaldi J, Soria D, et al. An end-to-end deep learning histochemical scoring system for breast Cancer TMA. IEEE Trans Med Imaging. 2019;38(2):617–28.
doi: 10.1109/TMI.2018.2868333
pubmed: 30183623
Tsuji G, Hashimoto-Hachiya A, Kiyomatsu-Oda M, Takemura M, Ohno F, Ito T, et al. Aryl hydrocarbon receptor activation restores filaggrin expression via OVOL1 in atopic dermatitis. Cell Death Dis. 2017;8(7):e2931.
doi: 10.1038/cddis.2017.322
pubmed: 28703805
pmcid: 5550867
Hashimoto-Hachiya A, Tsuji G, Murai M, Yan X, Furue M. Upregulation of FLG, LOR, and IVL expression by Rhodiola Crenulata Root Extract via Aryl Hydrocarbon receptor: Differential involvement of OVOL1. Int J Mol Sci. 2018;19(6):1654.
doi: 10.3390/ijms19061654
pubmed: 29866992
pmcid: 6032276
Gerritsen MJ, Elbers ME, de Jong EM, van de Kerkhof PC. Recruitment of cycling epidermal cells and expression of filaggrin, involucrin and tenascin in the margin of the active psoriatic plaque, in the uninvolved skin of psoriatic patients and in the normal healthy skin. J Dermatol Sci. 1997;14(3):179–88.
doi: 10.1016/S0923-1811(96)00570-1
pubmed: 9138475
Kim BE, Howell MD, Guttman-Yassky E, Gilleaudeau PM, Cardinale IR, Boguniewicz M, et al. TNF-α downregulates filaggrin and loricrin through c-Jun N-terminal kinase: role for TNF-α antagonists to improve skin barrier. J Invest Dermatol. 2011;131(6):1272–9.
doi: 10.1038/jid.2011.24
pubmed: 21346775
pmcid: 8609659
Jensen P, Skov L. Filaggrin in Psoriasis. In: Thyssen J, Maibach H, editors. Filaggrin. Berlin, Heidelberg: Springer; 2014. https://doi.org/10.1007/978-3-642-54379-1_26 .
doi: 10.1007/978-3-642-54379-1_26
Varma SR, Sivaprakasam TO, Mishra A, Prabhu S, Rafiq M, Rangesh P. Imiquimod-induced psoriasis-like inflammation in differentiated human keratinocytes: its evaluation using curcumin. Eur J Pharmacol. 2017;813:33–41.
doi: 10.1016/j.ejphar.2017.07.040
pubmed: 28736282
Smith SH, Jayawickreme C, Rickard DJ, Nicodeme E, Bui T, Simmons C, et al. Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans. J Invest Dermatol. 2017;137(10):2110–9.
doi: 10.1016/j.jid.2017.05.004
pubmed: 28595996
Di Meglio P, Duarte JH, Ahlfors H, Owens ND, Li Y, Villanova F, et al. Activation of the aryl hydrocarbon receptor dampens the severity of inflammatory skin conditions. Immunity. 2014;40(6):989–1001.
doi: 10.1016/j.immuni.2014.04.019
pubmed: 24909886
pmcid: 4067745
Furue M, Hashimoto-Hachiya A, Tsuji G. Aryl Hydrocarbon Receptor in atopic dermatitis and psoriasis. Int J Mol Sci. 2019;20(21):5424.
doi: 10.3390/ijms20215424
pubmed: 31683543
pmcid: 6862295
Furue K, Ito T, Tsuji G, Ulzii D, Vu YH, Kido-Nakahara M, Nakahara T, Furue M. The IL-13-OVOL1-FLG axis in atopic dermatitis. Immunology. 2019;158(4):281–6.
doi: 10.1111/imm.13120
pubmed: 31509236
pmcid: 6856930
Dębińska A. New treatments for atopic dermatitis targeting skin barrier repair via the regulation of FLG expression. J Clin Med. 2021;10(11):2506.
doi: 10.3390/jcm10112506
pubmed: 34198894
pmcid: 8200961